IQVIA (NYSE:IQV) shares slid Thursday. The company, priding itself on being “a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries,” today announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) technology offering as the accelerator to power its global commercial data harmonization and transformation journey.
This collaboration will enable Boehringer to scale its commercial data products and analytics ambitions across therapeutic areas and regional teams, leveraging an industry-leading global data model.
“We are excited about the possibilities of working with IQVIA’s Data as a Service (DaaS+) platform. By enabling the seamless ingestion of our global commercial data sets into a unified platform, directly integrated into our cloud infrastructure, we believe this platform would drive significant efficiencies in our data operations, including affording advanced analytics and innovative use cases, paving the way for transformative insights and decision-making,” said Justin Gale, Global Head of Data Excellence at Boehringer Ingelheim.
The collaboration supports upcoming launches and enhances existing market performance, providing harmonized data for all market, brand and franchise reporting across 59 countries. Boehringer will benefit from global product mastering, efficient data management and seamless access to IQVIA data for data-driven decision making.
IQV shares dropped $1.29 to $238.40.
